Oracle Runs

Will the results be positive?

Trial completed Jan 2026 per ClinicalTrials.gov. No public readout, topline results, sponsor PR, or interpretation found in searches as of Apr 2026. Primary endpoint data not posted; no sources frame outcomes positively or negatively.

Will the results be positive?

Trial (NCT04530123/TAK-101-2001) completed primary data collection Dec 2025 (recently updated listings as of Jan 2026). No public topline results, press release, or readout found despite targeted searches. Prior Phase 2a (different trial) was positive on the same ELISpot primary endpoint, but this is a distinct dose-ranging study. No clear framing of this exact trial as positive or negative.

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Will the results be positive?

No trial-specific public efficacy readout was found. As of Jan 29, 2026, Takeda still listed TAK-101 for celiac disease as a Phase 2 asset, and a CT.gov-tracking source checked Mar 11, 2026 still showed NCT04530123 as ongoing/results pending. That is insufficient to call the trial positive or negative.

Will the results be positive?

This exact Phase 2 trial is completed, but the public study record still says no results posted, and Takeda’s Jan 29, 2026 pipeline lists TAK-101 in Phase 2 without any trial-specific efficacy interpretation. No clear positive or negative readout found.